Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 2/20 | 0.67 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KIF20A | O95235 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | UNG | P13051 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12676007 | 0.87 | NEK2 (0.66) | NEK2MAP2K1KMT2AKIF20ACLK1 | |
| SCHEMBL12675734 | 0.85 | NEK2 (0.76) | NEK2MAP2K1KMT2AKIF20ACLK1 | |
| SCHEMBL14682666 | 0.84 | NEK2 (0.68) | NEK2MAP2K1KMT2AKIF20ACLK1 | |
| SCHEMBL857000 | 0.83 | NEK2 (0.58) | NEK2MAP2K1KMT2ACNR2KDR | |
| SCHEMBL16450324 | 0.83 | NEK2 (0.73) | NEK2MAP2K1KMT2AKIF20ACLK1 | |
| SCHEMBL12675990 | 0.82 | NEK2 (0.69) | NEK2MAP2K1KMT2AKIF20ACLK1 | |
| SCHEMBL878800 | 0.82 | NEK2 (0.57) | NEK2MAP2K1DYRK1ACLK4DYRK1B | |
| SCHEMBL858554 | 0.82 | NEK2 (0.57) | NEK2MAP2K1KMT2ACNR2KDR | |
| SCHEMBL3709076 | 0.82 | NEK2 (0.63) | NEK2MAP2K1KMT2ACLK2CDK5 | |
| SCHEMBL856986 | 0.82 | NEK2 (0.60) | NEK2MAP2K1KMT2ADYRK1ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505766-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505766-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150045343-A1 | KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-12 | — | — | US | disclosed |
| US-20150045343-A1 | KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-12 | — | — | US | disclosed |
| US-20150045343-A1 | KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-12 | — | — | US | disclosed |
| EP-2558099-A2 | KINASE INHIBITORS | The Regents Of The University Of California, San Francisco (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20130035325-A1 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035325-A1 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035325-A1 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | disclosed |
| WO-2011060440-A2 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011060440-A2 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035325-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K8 | NEK2 79/4885MAP2K1 81/4885KMT2A 1498/4885 |
| US-20150045343-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K8 | NEK2 79/4885MAP2K1 81/4885KMT2A 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.